Stockscreener 앱 받기
143.75
0.45%
0.64
Novartis Ag Adr 주식(NVS)의 최신 뉴스
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis wins FDA approval for a form of chronic hives - marketscreener.com
AI companies run virtual drug trials, aim to improve success of human studies - Reuters
Novartis AG (CEUX:1NOVNM) Cyclically Adjusted Price-to-FCF : (As of Oct. 07, 2026) - GuruFocus
US FDA expands use of Novartis drug for chronic skin condition - Reuters
Why Is Novartis Stock Trading Higher Today?Novartis (NYSE:NVS) - Benzinga
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Trea - GuruFocus
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) - The Manila Times
Novartis Rhapsido® (remibrutinib) receives FDA approval as - GlobeNewswire
Novartis to Present Key Data on Multiple Sclerosis - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - GlobeNewswire Inc.
Novartis advances multiple sclerosis innovation with - GlobeNewswire
The patient who changed the course of my career - Novartis
Novartis AG (SWX: NOVN): Now September Has Ended, Is It Now Time To Buy? - Stocks Down Under
Novartis Sues Apotex Over Mekinist Copies, Tafinlar Drug Combo - Bloomberg Law News
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026 - GlobeNewswire Inc.
BofA Expects Higher Q3 Sales From Novartis Amid Strong Key Growth Drivers - Moomoo
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Zacks Investment Research
Total non-current liabilities of Novartis AG – BX:NOT - TradingView
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion - Bloomberg.com
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Novartis faces securities fraud probe after dru... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - prnewswire.com
Novartis AG : Receives a Sell rating from Goldman Sachs - marketscreener.com
Novartis Falls as Investors Continue to Digest September Trial Setbacks - Quiver Quantitative
Novartis AG (CEUX:1NOVNm) Stock Price & 30 Year Financial Data - GuruFocus
Community health takes a village: from Pulpit to Pew - Novartis
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Gross margin % of Novartis AG Sponsored ADR – HAN:NOTA - TradingView
Net margin % of Novartis AG Sponsored ADR – HAN:NOTA - TradingView
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors - GuruFocus
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG : Deutsche Bank reiterates its Neutral rating - marketscreener.com
Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure? - Yahoo Finance
Novartis AG Stock Warning Signs - GuruFocus
Novartis AG Hired Firms, 2003 - OpenSecrets
Novartis AG Lobbyists, 1998 - OpenSecrets
Novartis AG Agencies, 2026 - OpenSecrets
Novartis AG Lobbyists, 2026 - OpenSecrets
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile - ChartMill
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? - Yahoo Finance
0.26%
자본화:
|
볼륨(24시간):